Problems and solutions in myoblast transfer therapy

Research output: Contribution to journalReview articlepeer-review

61 Citations (Scopus)


Duchenne muscular dystrophy is a severe X-linked neuromuscular disease that affects approximately 1/3500 live male births in every human population, and is caused by a mutation in the gene that encodes the muscle protein dystrophin. The characterization and cloning of the dystrophin gene in 1987 was a major breakthrough and it was considered that simple replacement of the dystrophin gene would ameliorate the severe and progressive skeletal muscle wasting characteristic of Duchenne muscular dystrophy. After 20 years, attempts at replacing the dystrophin gene either experimentally or clinically have met with little success, but there have been many significant advances in understanding the factors that limit the delivery of a normal dystrophin gene into dystrophic host muscle. This review addresses the host immune response and donor myoblast changes underlying some of the major problems associated with myoblast-mediated dystrophin replacement, presents potential solutions, and outlines other novel therapeutic approaches.
Original languageEnglish
Pages (from-to)33-47
JournalJournal of Cellular and Molecular Medicine
Issue number1
Publication statusPublished - 2001


Dive into the research topics of 'Problems and solutions in myoblast transfer therapy'. Together they form a unique fingerprint.

Cite this